Skip to main content

Quest, Health Discovery in Cancer Dx Licensing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed rights from Health Discovery Corp. and privately held firm Smart Personalized Medicine to develop laboratory tests that help determine appropriate breast cancer therapies.

The firms did not provide details on the licensed technologies. Under the terms of the agreements, Quest will pay health Discovery and SPM upfront licensing payments, development fees, and royalties on a per test basis.

Further terms were not disclosed.

Last year, Savannah, Ga.-based Health Discovery licensed to Quest rights to develop a new urine-based test for clinically significant prostate cancer.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.